Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia

被引：13
作者：
Nieborowska-Skorska, Margaret [1 ,2 ]
Maifrede, Silvia [1 ,2 ]
Ye, Min [3 ]
Toma, Monika [1 ,2 ,4 ]
Hewlett, Elizabeth [3 ]
Gordon, John [3 ]
Bac Viet Le [1 ,2 ,5 ]
Sliwinski, Tomasz [4 ]
Zhao, Huaqing [6 ]
Piwocka, Katarzyna [5 ]
Valent, Peter [7 ,8 ]
Tulin, Alexei V. [9 ]
Childers, Wayne [3 ]
Skorski, Tomasz [1 ,2 ]
机构：
[1] Temple Univ, Lewis Katz Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA
[2] Temple Univ, Lewis Katz Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA
[3] Temple Univ, Sch Pharm, Moulder Ctr Drug Discovery Res, Philadelphia, PA 19122 USA
[4] Univ Lodz, Fac Biol & Environm Protect, Lab Med Genet, Lodz, Poland
[5] Nencki Inst Expt Biol, Lab Cytometry, Warsaw, Poland
[6] Temple Univ, Dept Clin Sci, Lewis Katz Sch Med, Philadelphia, PA 19122 USA
[7] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[8] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria
[9] Univ North Dakota, Dept Biomed Sci, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 04期
基金：
奥地利科学基金会;
关键词：
MECHANISMS;
D O I：
10.1080/10428194.2018.1520988
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1098 / 1101
页数：4
相关论文
共 15 条
  • [1] DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Bartkova, J
    Horejsi, Z
    Koed, K
    Krämer, A
    Tort, F
    Zieger, K
    Guldberg, P
    Sehested, M
    Nesland, JM
    Lukas, C
    Orntoft, T
    Lukas, J
    Bartek, J
    [J]. NATURE, 2005, 434 (7035) : 864 - 870
  • [2] Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair
    Bird, AW
    Yu, DY
    Pray-Grant, MG
    Qiu, QF
    Harmon, KE
    Megee, PC
    Grant, PA
    Smith, MM
    Christman, MF
    [J]. NATURE, 2002, 419 (6905) : 411 - 415
  • [3] The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
    Dkhissi, Fatima
    Aggoune, Djamel
    Pontis, Julien
    Sorel, Nathalie
    Piccirilli, Nathalie
    LeCorf, Amelie
    Guilhot, Francois
    Chomel, Jean-Claude
    Ait-Si-Ali, Slimane
    Turhan, Ali G.
    [J]. EXPERIMENTAL HEMATOLOGY, 2015, 43 (09) : 775 - 780
  • [4] Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
    Hehlmann, R.
    Lauseker, M.
    Saussele, S.
    Pfirrmann, M.
    Krause, S.
    Kolb, H. J.
    Neubauer, A.
    Hossfeld, D. K.
    Nerl, C.
    Gratwohl, A.
    Baerlocher, G. M.
    Heim, D.
    Bruemmendorf, T. H.
    Fabarius, A.
    Haferlach, C.
    Schlegelberger, B.
    Mueller, M. C.
    Jeromin, S.
    Proetel, U.
    Kohlbrenner, K.
    Voskanyan, A.
    Rinaldetti, S.
    Seifarth, W.
    Spiess, B.
    Balleisen, L.
    Goebeler, M. C.
    Haenel, M.
    Ho, A.
    Dengler, J.
    Falge, C.
    Kanz, L.
    Kremers, S.
    Burchert, A.
    Kneba, M.
    Stegelmann, F.
    Koehne, C. A.
    Lindemann, H. W.
    Waller, C. F.
    Pfreundschuh, M.
    Spiekermann, K.
    Berdel, W. E.
    Mueller, L.
    Edinger, M.
    Mayer, J.
    Beelen, D. W.
    Bentz, M.
    Link, H.
    Hertenstein, B.
    Fuchs, R.
    Wernli, M.
    [J]. LEUKEMIA, 2017, 31 (11) : 2398 - 2406
  • [5] Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
    Karanam, Ketki
    Kafri, Ran
    Loewer, Alexander
    Lahav, Galit
    [J]. MOLECULAR CELL, 2012, 47 (02) : 320 - 329
  • [6] Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
    Lord, Christopher J.
    Tutt, Andrew N. J.
    Ashworth, Alan
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 455 - 470
  • [7] Mechanisms of resistance to therapies targeting BRCA-mutant cancers
    Lord, Christopher J.
    Ashworth, Alan
    [J]. NATURE MEDICINE, 2013, 19 (11) : 1381 - 1388
  • [8] Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
    Murai, Junko
    Huang, Shar-yin N.
    Das, Benu Brata
    Renaud, Amelie
    Zhang, Yiping
    Doroshow, James H.
    Ji, Jiuping
    Takeda, Shunichi
    Pommier, Yves
    [J]. CANCER RESEARCH, 2012, 72 (21) : 5588 - 5599
  • [9] Nickoloff JA, 2017, J NATL CANC I, V109, P1
  • [10] Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
    Nieborowska-Skorska, Margaret
    Sullivan, Katherine
    Dasgupta, Yashodhara
    Podszywalow-Bartnicka, Paulina
    Hoser, Grazyna
    Maifrede, Silvia
    Martinez, Esteban
    Di Marcantonio, Daniela
    Bolton-Gillespie, Elisabeth
    Cramer-Morales, Kimberly
    Lee, Jaewong
    Li, Min
    Slupianek, Artur
    Gritsyuk, Daniel
    Cerny-Reiterer, Sabine
    Seferynska, Ilona
    Stoklosa, Tomasz
    Bullinger, Lars
    Zhao, Huaqing
    Gorbunova, Vera
    Piwocka, Katarzyna
    Valent, Peter
    Civin, Curt I.
    Muschen, Markus
    Dick, John E.
    Wang, Jean C. Y.
    Bhatia, Smita
    Bhatia, Ravi
    Eppert, Kolja
    Minden, Mark D.
    Sykes, Stephen M.
    Skorski, Tomasz
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (06) : 2392 - 2406
12